泛素蛋白酶体抑制剂MG-132与心力衰竭  

Ubiquitin Proteasome Inhibitor MG-132 and Heart Failure

作　　者：杨伟 段显凤 陈章荣 YANG Wei;DUAN Xianfeng;CHEN Zhangrong(The First Affiliated Hospital of Dali University,Dali 671000,Yunnan,China)

机构地区：[1]大理大学第一附属医院心内科

出　　处：《心血管病学进展》2020年第1期60-62,共3页Advances in Cardiovascular Diseases

基　　金：云南省教育厅科研项目(2019J0766)

摘　　要：心力衰竭是各种心脏疾病发展的严重阶段,发病率的上升是心血管医学面临的最大挑战之一,已成为心脏病治疗的最后战场。MG-132是一种泛素蛋白酶体抑制剂,其在心力衰竭发展过程中扮演重要的角色,但其具体作用尚未完全阐明。现综述MG-132与心力衰竭关系及相关分子机制。Heart failure is a serious stage of the development of various heart diseases. The rising incidence of heart failure is one of the biggest challenges facing cardiovascular medicine,and it has become the final battleground for heart disease treatment. MG-132 is a ubiquitin proteasome inhibitor,which plays an important role in the development of heart failure,but its specific role has not been fully clarified. This article reviews the relationship between MG-132 and heart failure and its molecular mechanism.

关 键 词：心力衰竭 MG-132 泛素蛋白酶体系统 

分 类 号：R541.6[医药卫生—心血管疾病]